Tetra Discovery Partners announced the initiation of a Phase II study of BPN14770, which targets phosphodiesterase-4D, or PDE4D. The trial is expected to enroll about 255 patients at 60 sites in the US.
Visits to three health systems — Mercy Health in Grand Rapids, Michigan; Henry Ford Health System in Detroit; and OSF HealthCare in Peoria, Illinois — showcase how they're thinking creatively about simulation, startups, 3D printing and more.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!